Monovalent Influenza Vaccine A

Vaccine

BButantan Institute

Monovalent Influenza Vaccine A is one of 18 biologic programs targeting Influenza. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

InfluenzaActive, not recruiting

InfluenzaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1053 competitors in Influenza

#DrugCompanyPhaseTrials

Fluzone

Sanofi

Preclinical

16 2

Fluzone

GSK

Preclinical

37 3

Trexall

Alnylam Pharmaceuticals

Preclinical

1 4

Crestor

AstraZeneca

Preclinical

1 5

Avigan

AAppili Therapeutics Inc.

Preclinical

6 6

Quadrivalent Influenza Vaccine

Sanofi

Preclinical

30 7

COMIRNATY

Pfizer

Preclinical

1 8

Influenza A/H5N1

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

14 9

PD-1/PD-L1 Inhibitors

CChuangzhen Chen

Preclinical

1 10

Fluvirin

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Influenza1 trial

Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older Adults

Recruiting·BButantan Institute·Phase 1/2·NCT06842173·700 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Monovalent Influenza Vaccine A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Monovalent Influenza Vaccine A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Monovalent Influenza Vaccine A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Butantan Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Company: BButantan Institute

Monovalent Influenza Vaccine A

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Influenza1 trial

References

Drug Info

Quick Facts

Related News